JHVEPhoto/iStock Editorial via Getty Images
- Merck (NYSE:MRK) and its partner Sichuan Kelun-Biotech said that phase 3 data on their anbtibody drug candidate sacituzumab tirumotecan (sac-TMT) led to a 69% reduction in the risk of progression or death in those with triple-negative breast cancer.
- Of the 233 individuals enrolled, 26% had been on PD-1/PD-L1 inhibitors before and 48% received at least three prior lines of chemotherapy.
- Additional data indicated that progression-free survival was 5.7 months with sac-TMT vs 2.3 months with chemotherapy.
- The objective response rate was 43.8% with sac-TMT and 12.8% with chemotherapy.
- The most common grade ≥ 3 treatment-related adverse events (sac-TMT vs. chemotherapy) were lowered neutrophil count (32.3% vs. 47%), anemia (27.7% vs. 6.1%), and decreased white blood cell count (25.4% vs. 36.4%).
- The results will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2.
